EPZM Epizyme, Inc.

-0.30  -2%
Previous Close 16.45
Open 16.45
Price To book 5.50
Market Cap 942.48M
Shares 58,358,000
Volume 670,983
Short Ratio 8.48
Av. Daily Volume 444,833

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due at ASCO 2017 - June 4, 2017. Abstract 11057.
Solid tumors - cancer
Phase 2 dosing commenced August 2016. Enrollment to be completed in 2017.
Adult patients with mesothelioma characterized by BAP1 loss-of-function
Phase 2 futility analysis completed September 6, 2016. Futher data due at The International Conference on Malignant Lymphoma (ICML) - June 14, 2017.
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma

Latest News

  1. 3 Stocks With iRobot-Like Return Potential
  2. Epizyme, Inc. breached its 50 day moving average in a Bearish Manner : EPZM-US : May 26, 2017
  3. Implied Volatility Surging for Epizyme (EPZM) Stock Options
  4. Epizyme Announces Path Toward Tazemetostat Registration in Epithelioid Sarcoma and Reports New Clinical Data to be Presented at ASCO
  5. Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth
  6. Today's Research Reports on Stocks to Watch: Insys Therapeutics and Epizyme
  7. Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q1
  8. Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss
  9. Epizyme reports 1Q loss
  10. Epizyme Reports First Quarter 2017 Results and Provides Corporate Update
  11. 3 Intriguing Cancer Drugs With Data Coming at ASCO Next Month
  12. Epizyme Earns $10 Million Milestone Payment from GlaxoSmithKline for Initiation of GLP Toxicology Studies with Novel Methyltransferase Inhibitor
  13. What to Expect from Epizyme (EPZM) This Earnings Season?
  14. Epizyme, Inc. – Value Analysis (NASDAQ:EPZM) : April 27, 2017
  15. Epizyme, Inc. breached its 50 day moving average in a Bullish Manner : EPZM-US : April 26, 2017
  16. Why Epizyme Inc. Shares Are Soaring Today
  17. Epizyme Announces Tazemetostat Fast Track Designation for Follicular Lymphoma and Plenary Session on Phase 2 NHL Data at ICML
  18. Epizyme Announces Date of First Quarter 2017 Financial Results and Tazemetostat Data Presentations at ASCO